338 related articles for article (PubMed ID: 30628065)
21. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.
Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T
Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093
[TBL] [Abstract][Full Text] [Related]
22. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract][Full Text] [Related]
23. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases.
Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X
J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851
[TBL] [Abstract][Full Text] [Related]
24. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
25. Proteomic identification of Reticulocalbin 1 as potential tumor marker in renal cell carcinoma.
Giribaldi G; Barbero G; Mandili G; Daniele L; Khadjavi A; Notarpietro A; Ulliers D; Prato M; Minero VG; Battaglia A; Allasia M; Bosio A; Sapino A; Gontero P; Frea B; Fontana D; Destefanis P
J Proteomics; 2013 Oct; 91():385-92. PubMed ID: 23916412
[TBL] [Abstract][Full Text] [Related]
26. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED
JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025
[TBL] [Abstract][Full Text] [Related]
28. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
29. Role Of Immunohistochemistry In Subtyping Renal Cell Carcinomas With Overlapping Morphological Features.
Tariq N; Mamoon N; Haroon A; Ali Z; Ahmad IN
J Ayub Med Coll Abbottabad; 2018; 30(3):325-332. PubMed ID: 30465359
[TBL] [Abstract][Full Text] [Related]
30. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
[TBL] [Abstract][Full Text] [Related]
31. Searching for prognostic biomarkers for small renal masses in the urinary proteome.
Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MA; Diamandis EP; Yousef GM
Int J Cancer; 2020 Apr; 146(8):2315-2325. PubMed ID: 31465112
[TBL] [Abstract][Full Text] [Related]
32. Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
Lai JZ; Lai HH; Cao D
Anticancer Res; 2018 Jun; 38(6):3757-3761. PubMed ID: 29848739
[TBL] [Abstract][Full Text] [Related]
33. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological significance of matrix metalloproteinase 2 protein expression in patients with renal cell carcinoma: A case-control study and meta-analysis.
Liu Q; Zhang GW; Zhu CY; Wei JX; Tian X; Li Y; Li XD
Cancer Biomark; 2016; 16(2):281-9. PubMed ID: 26756619
[TBL] [Abstract][Full Text] [Related]
35. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
36. COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis.
Tabriz HM; Mirzaalizadeh M; Gooran S; Niki F; Jabri M
Asian Pac J Cancer Prev; 2016; 17(2):535-8. PubMed ID: 26925639
[TBL] [Abstract][Full Text] [Related]
37. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
38. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
39. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
[TBL] [Abstract][Full Text] [Related]
40. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes.
Parekh DJ; Cookson MS; Chapman W; Harrell F; Wells N; Chang SS; Smith JA
J Urol; 2005 Jun; 173(6):1897-902. PubMed ID: 15879771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
